Imatinib mesylate in chronic myeloid leukemia

Current Stem Cell Research and Therapy

Volumn 2, Issue 3, 2007, Pages 249-251

  Carella, Angelo Michele ^a   Lerma, Enrica ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Abl; Molecular monitoring; Resistance; Treatment guidelines; Tyrosine kinase inhibitor

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; CYTARABINE; DASATINIB; HYDROXYUREA; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TARGETING; DRUG WITHDRAWAL; ENZYME ACTIVITY; FATIGUE; FLUID RETENTION; HUMAN; MUSCULOSKELETAL DISEASE; MUTATIONAL ANALYSIS; NEUTROPENIA; PATIENT MONITORING; PHARMACOGENETICS; POINT MUTATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; PIPERAZINES; PRACTICE GUIDELINES AS TOPIC; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 34848924266     PISSN: 1574888X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488807781696276     Document Type: Review

References (14)

1. Barnes DJ, Melo JV. Cytogenetic and molecular genetic aspects of chronic myeloid leukaemia. Acta Haematol 2002; 180: 180-202
2. Druker BJ, Tamura S, Buchdungher E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-6
3. Mauro MI. Defining and managing Imatinib resistance. Hematology 2006; 219-25.
4. Druker B, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-17.
5. Kantarjian H, Talpaz M, O'Brien S, et al. Survival benefit with imatinib mesylate versus interferon-α-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood 2006; 108: 1835-40
6. Shah NP. Improving upon the promise of targeted therapy of human malignancy: chronic myeloid leukemia as a paradigm. Cancer Chemother Pharmacol 2006; 58: 49-53
7. Wei Y, Hardling M, Olsson B, et al. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations. Ann Hematol 2006; 85: 841-7
8. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108: 1809-1820
9. Martinelli G, lacobucci I, Soverini S, et al. Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management. Hematol Oncol 2006; 24: 196-204
10. Branford S, Cross NC, Hochhaus A, et al. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with, chronic myeloid leukemia. Leukemia 2006; 20: 1925-30
11. Roeder I, Horn M, Glauche I, Hochhaus A, Mueller MC, Loeffler, M. Dynamic modelling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat Med 2006; 12: 1181-4
12. Barnes DJ, Melo JV. Primitive, Quiescent and Difficult to Kill: The Role of Non-Proliferating Stem Cells in Chronic Myeloid Leukemia. Cell Cycle 2006, 3(24): 2862-6.
13. Ohno R. Treatment of chronic myeloid leukemia with imatinib mesylate. Int J Clin Oncol 2006; 11: 176-83
14. Giles FJ, Cortes JE, Jones D, Bergstrom DA, Kantarjian HM, Freedman SJ. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T3151,BCR-ABL mutation. Blood 2006; 109(2): 500-2.